NAD+: what the human research actually shows
The central editorial point is this: NAD+ is not a peptide. The human data that exists is mostly about oral precursors raising blood NAD+ levels, not about whether raising those levels changes how you feel, function, or age.
Why I looked into this
NAD+ shows up on every peptide vendor list, in every wellness clinic menu, and in roughly half the longevity podcasts I sample. The pitch usually bundles three claims: it falls with age, restoring it slows aging, and IV infusion is the fastest way to restore it.
I went looking for the human trial record because readers of this site keep asking me whether the IV clinic experience is worth it. What I found is a story that starts with a real biological molecule, picks up some small human trials on oral precursors, and then runs off a cliff into marketing territory when it gets to IV infusion.
What NAD+ actually is
Nicotinamide adenine dinucleotide, written NAD+ in its oxidized form, is a coenzyme every living human cell already makes and uses. It shuttles electrons in metabolism, participates in DNA repair through PARP enzymes, and is consumed by the sirtuin family of longevity-linked enzymes.
Chemically, it is a dinucleotide built from nicotinamide and adenine connected by two ribose sugars and two phosphate groups. It is not a peptide. It contains no peptide bonds. The reason it lives on peptide vendor sites and in this monograph series is commercial adjacency, not biochemistry. Oral precursor forms (nicotinamide riboside, NR, and nicotinamide mononucleotide, NMN) are what most human trials have actually tested, because direct NAD+ does not cross the cell membrane easily on its own.
What the human research shows
Do published human trials exist?
Yes, for oral precursors. Small human trials of NR and NMN have been published and are indexed on PubMed. The quality and size are modest, and the endpoints are mostly biomarker and tolerability rather than clinical.
For direct intravenous NAD+ as sold at wellness clinics, the published human trial record is much thinner. A handful of observational reports and small open-label series exist, primarily in addiction-recovery settings and in a pilot Parkinson’s study. There is no large randomized controlled trial of IV NAD+ for anti-aging, cognitive, or metabolic endpoints that I could find.
So the honest picture is: oral precursor human data exists and is modest; direct IV NAD+ human data is mostly anecdotal.
What evidence actually exists?
The most-cited human studies are:
- Martens et al., Nature Communications, 2018: a randomized placebo-controlled crossover in 24 healthy middle-aged and older adults. Oral nicotinamide riboside raised blood NAD+ and was well tolerated. Changes in blood pressure and aortic stiffness were small and not statistically robust.
- Elhassan et al., Cell Reports, 2019: 21-day oral NR in 12 aged men. Raised muscle NAD+ and altered the skeletal-muscle metabolome. No change in mitochondrial function or muscle strength.
- Conze et al., Scientific Reports, 2019: eight-week oral NR in healthy overweight adults. Safe and tolerable, raised whole-blood NAD+, no significant change in most metabolic endpoints.
- Grant et al., Frontiers in Aging Neuroscience, 2019: a pilot of IV NAD+ in a small number of adults, looking at pharmacokinetics and plasma levels over an infusion. Pharmacokinetic paper, not a clinical outcomes trial.
- Yoshino et al., Science, 2021: oral NMN in postmenopausal women with prediabetes. Improved muscle insulin sensitivity by one measure; small sample, specific population.
What the research does not show
The research does NOT show:
- That IV NAD+ infusion at a wellness clinic slows aging. No randomized trial has tested that claim.
- That raising blood or muscle NAD+ levels produces the downstream longevity outcomes (extended lifespan, reduced mortality, large functional gains) the marketing implies.
- That oral NR or NMN improves cognition, energy, or subjective wellbeing at the scale the influencer discourse suggests. Most trials show biomarker shifts with small or null clinical effects.
- Any equivalence between oral precursor trials and IV NAD+ claims. They are different interventions with different evidence.
- Safety of repeated, high-volume IV NAD+ infusion over years. No long-term surveillance cohort has been published.
The gap between “oral NR raises blood NAD+ by a measurable amount” and “IV NAD+ therapy turns aging back” is the gap between the trials and the pitch.
Known safety signals in humans
Oral NR and NMN appear well tolerated in the short-term trials published so far, with mild gastrointestinal complaints being the most common report. Longer-term safety in healthy adults is essentially unknown past the 12-week window most trials used.
IV NAD+ infusion carries the general risks of any IV procedure (infection, extravasation, infusion-site reaction) plus the reported subjective discomfort during rapid infusion that has led most clinics to slow the drip substantially. There is no published pharmacovigilance data tracking repeated IV NAD+ use over years, and reported adverse events from the wellness-clinic market are captured inconsistently if at all.
FDA and legal status in the US
The US regulatory picture here has two lanes. Oral NAD+ precursors (NR, NMN) sit in the supplement framework. They are not drugs, not evaluated for efficacy by FDA, and not held to pharmaceutical-grade identity standards. The FDA has taken specific enforcement action against NMN as a supplement ingredient in recent years, which is worth tracking if you buy oral product.
IV NAD+ infusion sits in a different lane: a clinician-administered compounded or repackaged product delivered under medical supervision. It is not an FDA-approved drug. The compound is not on the 503A bulk drug substances list. Wellness clinics administer it under state medical practice laws and physician discretion, not under an FDA-approved indication.
How to evaluate a source: the safety framework
Why this section exists: people are going to look for sources whether I help or not. My goal here is harm reduction, not facilitation. I do not name vendors. I do not link to sellers. I am teaching you how to think about a source so you can have an informed conversation with a clinician.
- Licensed 503A compounding pharmacy
- Third-party certificate of analysis
- Requires a valid prescription
- US-based with verifiable physical address
- Transparent about what they compound and what they do not
- Anonymous crypto-only payment
- “Research use only” labeling loophole
- No COA or in-house testing only
- No physical address or phone contact
- Willingness to sell Category 2 substances for human use
The wrinkle for NAD+ specifically
The specific source-safety problem with NAD+ is that it splits across two very different markets. Oral supplements (NR, NMN) are sold through normal supplement channels, where identity and purity are patchy and third-party testing is optional. The FDA’s enforcement stance on NMN has moved more than once, so what is on the shelf today may not be on the shelf next year.
IV infusion is the messier market. Wellness clinics vary enormously in who supervises the infusion, where the NAD+ material comes from, how it is compounded, and what the pre-infusion clinical assessment looks like. A clinic can look sophisticated and still be using loosely sourced material with no independent testing. The label “medical clinic” does not guarantee pharmaceutical-grade input.
Cost reality
Oral precursor products from supplement brands vary widely in price, with the well-known NR and NMN brands landing in the premium supplement tier. A licensed 503A compounding pharmacy is not typically the source for oral supplements.
IV NAD+ infusion at a wellness clinic is expensive per visit and scales into multi-session packages that can become a meaningful recurring cost. Cost does not correlate with evidence. A more expensive clinic is not giving you a better-studied intervention; it is giving you a nicer lobby and possibly a slower drip.
Questions worth asking any source
- For oral precursor products: is there a third-party certificate of analysis confirming the listed ingredient and quantity?
- For IV infusion clinics: where is the NAD+ material sourced, who compounds it, and can you see a certificate of analysis?
- Is the infusion supervised by a licensed clinician who takes a history and reviews contraindications before the first session?
- What is the clinic’s process when a patient reacts poorly during infusion? Who handles it?
- Is the clinic recording adverse events in a way that could ever become useful data, or is the reporting informal?
My honest take
Opinion, not evidence
This section is opinion. I am not endorsing use of this peptide. Everything above this line is sourced from the published record. Everything below is my personal perspective as one pseudonymous reader and one person who has used this peptide. Your situation is not my situation. Do not treat this as a recommendation.
I have not used NAD+. Not as an oral supplement, not as an IV infusion. If I were going to try raising NAD+ levels today, I would start with an oral precursor in a trial-tested form before I ever considered paying a wellness clinic for an infusion, because the human evidence floor for oral precursors is at least visible, and the floor for IV infusion is essentially the clinic’s word.
The single biggest editorial point I want readers to leave with is that NAD+ is not a peptide. The reason it ended up on every peptide vendor list and in every peptide-curious conversation is that the same retail channels sell both. Conflating a dinucleotide coenzyme with signaling peptides muddies the conversation about what any of these compounds actually do.
The oral precursor trials show that you can raise blood NAD+ with an oral dose. That is a real finding. What they do not show is that raising blood NAD+ produces the clinical outcomes that get pitched in wellness-clinic marketing. Most of the Phase 2-sized trials landed on small or null results for the endpoints readers actually care about: energy, cognition, function, aging.
For someone who is curious, read Martens 2018 and Elhassan 2019 before you read any clinic’s landing page. For someone considering use, I would not pay for IV infusion until a serious randomized trial with a real clinical endpoint exists, because what you are buying is a pharmacokinetic effect with an unproven clinical upside. For someone who has already decided, at minimum ask the clinic the sourcing and supervision questions above and expect honest answers.
Questions to ask your doctor
If you are considering NAD+, or if you are already using it and want to have an honest conversation with a clinician, these are the questions I would bring in with me.
- I have been reading about NAD+ oral precursors and IV infusion. Are you familiar with the published human trial data, and do you see a clinical reason any of it would be worth discussing in my specific situation?
- If I were curious about energy, cognitive, or aging-related concerns, what conventional or better-evidenced options would you want to rule in or out first?
- What baseline labs would you want to see before any supplement or IV intervention that affects metabolism or cellular energy pathways?
- Given the distinction between oral precursors (real but modest human data) and IV infusion (minimal randomized evidence), how would you weigh the two if a patient asked?
- If I developed unusual symptoms during or after a wellness-clinic infusion (chest discomfort, unusual fatigue, mood change), what should I do and who should I contact first?
- Is there any underlying condition you would want to rule out before I spent money on a longevity-framed intervention like IV NAD+?
What to do next
Read the actual trials
Start with Martens 2018 in Nature Communications and Elhassan 2019 in Cell Reports. Both are on oral precursors. Both are small. Notice what they actually measured.
Open the primer →Separate the two lanes
Oral precursor and IV infusion are different products with different evidence and different questions. Bring the visit-prep packet and decide which lane you are actually asking about.
Get the packet →Ask the clinic the hard questions
If you are going to an IV clinic anyway, ask about material sourcing, clinician supervision, and adverse-event handling. The 503A checklist adapts to this setting.
Open the checklist →Sources
- Martens CR, Denman BA, Mazzo MR, et al. “Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults.” Nature Communications. 2018;9(1):1286. PMID 29599478.
- Elhassan YS, Kluckova K, Fletcher RS, et al. “Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures.” Cell Reports. 2019;28(7):1717-1728.e6. PMID 31412242.
- Conze D, Brenner C, Kruger CL. “Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults.” Scientific Reports. 2019;9(1):9772. PMID 31278280.
- Grant R, Berg J, Mestayer R, et al. “A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+.” Frontiers in Aging Neuroscience. 2019;11:257. PMID 31616285.
- Yoshino M, Yoshino J, Kayser BD, et al. “Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women.” Science. 2021;372(6547):1224-1229. PMID 33888596.
- FDA. Various guidance and enforcement communications on NMN as a dietary supplement ingredient. Monitor the FDA supplement guidance pages for current status.
I cite sources above to show the reader what is available to read. Inclusion does not imply endorsement of any claim. Every preclinical reference is flagged as animal or in-vitro only.
Related monographs
Glutathione
Another compound that gets bundled with peptides by vendors but sits in a different chemical category. Human trials exist and are mostly disappointing against the marketing.
Epitalon
The flagship longevity peptide in the Russian bioregulator program. Real human data, single-source, no independent replication.
5-Amino-1MQ
A related small molecule marketed under the peptide umbrella with essentially no human clinical data. Same category-error problem.